BLSM

BlossomHill Therapeutics Inc

25.71

Sep 18 • 3:59 PM ET -1.11 (-4.14%)

25.74

Aftermarket • 4:16 PM ET +0.03 (0.12%)

Healthcare Biotechnology USA Small NASD

Today, 10:15 AMBlossomHill Therapeutics posts Q2 2026 loss with non-GAAP EPS -8.75, revenue $0, and cash runway into Q2 2028

Held by: VTI VXF VTWO VTWG VTWV VTHR

Scroll to Statements

Index	-
Market Cap	787.85M
Enterprise Value	972.66M
Income	-
Sales	-
Book/sh	-5.70
Cash/sh	3.11
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	63
IPO	Aug 07, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	8.26
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	7.37
Current Ratio	5.42
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.87
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Sep 18 BMO
EPS/Sales Surpr.	-844.92% -

Insider Own	30.01%
Insider Trans	20.65%
Inst Own	17.70%
Inst Trans	15.97%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	23.21%
SMA50	33.20%
SMA200	33.20%
Trades

Shs Outstand	30.64M
Shs Float	21.45M
Short Float	0.52%
Short Ratio	0.42
Short Interest	0.11M
52W High	27.80 -7.52%
52W Low	15.25 68.59%
Volatility	10.59% 8.35%
ATR (14)	1.68
RSI (14)	72.31
Beta	-
Rel Volume	2.72
Avg Volume	263.01K
Volume	715,139

Perf Week	23.25%
Perf Month	59.00%
Perf Quarter	-
Perf Half Y	-
Perf YTD	63.24%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	32.20
Prev Close	26.82
Price	25.71
Change %	-4.14%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-01-26	Initiated	JP Morgan	Overweight	$28
Sep-01-26	Initiated	H.C. Wainwright	Buy	$35
Sep-01-26	Initiated	Guggenheim	Buy	$30

Today 07:00AM	BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Sep-15-26 10:13AM	BlossomHill Therapeutics Shares Rise 4.4% After BH-30643 Trial Update (InvestorsHub)
07:00AM	BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer (GlobeNewswire)
Sep-03-26 07:00AM	BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
Sep-01-26 07:00AM	BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer (GlobeNewswire)
07:00AM	Loading…
Aug-18-26 07:00AM	BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC (GlobeNewswire)

Blossomhill Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded on June 22, 2020 and is headquartered in San Diego, CA.

PhDJing Rong Jean Cui

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GORDON CARL L	Director	Aug 10 '26	Buy	16.00	625,000	10,000,000	2,714,279	Aug 12 04:46 PM
ORBIMED ADVISORS LLC	Director	Aug 10 '26	Buy	16.00	625,000	10,000,000	2,714,279	Aug 12 04:43 PM
Schmid John P.	Director	Aug 10 '26	Buy	16.00	6,000	96,000	6,000	Aug 10 06:35 PM
Chen Bihua	Director	Aug 10 '26	Buy	16.00	312,500	5,000,000	3,614,034	Aug 10 06:32 PM
Keyes Jason A	Chief Financial Officer	Aug 10 '26	Buy	16.00	700	11,200	700	Aug 10 06:27 PM
Liptak Vincent Paul	General Counsel	Aug 07 '26	Buy	15.80	2,500	39,500	109,212	Aug 10 06:26 PM
Liptak Vincent Paul	General Counsel	Aug 10 '26	Buy	16.00	2,200	35,200	111,412	Aug 10 06:26 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BLSM

BlossomHill Therapeutics Inc

Upgrade your Finviz experience